• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    B. Riley Securities resumed coverage on Eton Pharmaceuticals with a new price target

    10/14/21 7:59:42 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email
    B. Riley Securities resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $10.00
    Get the next $ETON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETON

    DatePrice TargetRatingAnalyst
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    1/10/2025$21.00Buy
    B. Riley Securities
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    5/6/2024$8.00Buy
    Craig Hallum
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/25/24 4:05:24 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/8/24 6:34:32 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/16/25 4:56:08 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Brynjelsen Sean sold $3,592,611 worth of shares (210,000 units at $17.11), decreasing direct ownership by 7% to 2,873,513 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/5/25 5:15:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care